2 years ago

Causaly Secures $60 Million in Series B Funding to Advance AI for Biomedical Research

  • Causaly, a London and Athens-based AI platform for biomedical research, has raised $60 million in Series B funding, bringing its total funding to $93 million

  • Led by ICONIQ Growth, the round also saw participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures, Visionaries Club, and strategic individuals like Alex Gorsky (former CEO of Johnson & Johnson) and Olivier Pomel (CEO of Datadog)

  • Causaly's platform helps Life Sciences organizations discover, analyze, and apply data in drug discovery and development, accelerating the process from bench research to therapy launch

  • The company plans to use the funds to expand its product lead and commercial relationships.

      • ProblemHealthcare

      "Biomedical researchers are struggling to find, analyze and apply data in critical decision-making processes in drug discovery and development."

      Solution

      "Causaly provides an AI platform that enables researchers to conduct deep, unbiased scientific exploration, accelerating the journey from bench research to the launch of therapies."

      Covered on